Vanguard Group Inc Outlook Therapeutics, Inc. Transaction History

Vanguard Group Inc

11 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q4 2023 Feb 14, 2024	BUY	$0.22 - $0.66 $61,011 - $183,035	277,326 Added 4.41%	6,560,400 $2.56 Million
Q3 2023 Nov 14, 2023	BUY	$0.2 - $1.78 $26,989 - $240,203	134,946 Added 2.19%	6,283,074 $1.38 Million
Q2 2023 Aug 14, 2023	BUY	$1.02 - $1.89 $140,342 - $260,046	137,591 Added 2.29%	6,148,128 $10.7 Million
Q1 2023 May 15, 2023	BUY	$1.0 - $1.35 $347,876 - $469,632	347,876 Added 6.14%	6,010,537 $6.55 Million
Q4 2022 Feb 10, 2023	BUY	$0.87 - $1.33 $39,371 - $60,189	45,255 Added 0.81%	5,662,661 $6.12 Million
Q3 2022 Nov 14, 2022	SELL	$1.02 - $1.26 $2,274 - $2,809	-2,230 Reduced 0.04%	5,617,406 $6.85 Million
Q2 2022 Aug 12, 2022	SELL	$0.91 - $2.01 $14,999 - $33,130	-16,483 Reduced 0.29%	5,619,636 $5.73 Million
Q1 2022 May 13, 2022	SELL	$1.22 - $2.03 $403,978 - $672,193	-331,130 Reduced 5.55%	5,636,119 $10 Million
Q4 2021 Feb 14, 2022	BUY	$1.27 - $2.23 $1.56 Million - $2.74 Million	1,227,070 Added 25.89%	5,967,249 $8.12 Million
Q3 2021 Nov 12, 2021	BUY	$2.12 - $2.76 $224,230 - $291,922	105,769 Added 2.28%	4,740,179 $10.3 Million
Q2 2021 Aug 13, 2021	BUY	$1.78 - $2.76 $8.25 Million - $12.8 Million	4,634,410 New	4,634,410 $11.5 Million

31.5K

Ticker OTLK
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 226,144,992
Market Cap $1.26B
Description
Outlook Therapeutics, Inc., a late clinical-stage biopharmaceutical company, focuses on developing and commercializing monoclonal antibodies for various ophthalmic indications. Its lead product candidate is ONS-5010, an ophthalmic formulation of bevacizumab product candidate that is in Phase-III clinical trial for the treatment of wet age-relate...

Get notified when there are updates to the investment portfolio of Vanguard Group Inc, based on Form 13F filings with the SEC.

Stay updated on Vanguard Group Inc with notifications on news.